NEWSWIRETODAY Press Release& Newswire Distribution | HOME
PRTODAY / NewswireToday press release distribution service network
Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PRECOS Partners with Reliable Cancer Therapies - PRECOS partners with reliable cancer therapies to provide rigorous scientific evidence for complementary cancer medicines - /
PRECOS Partners with Reliable Cancer Therapies


NewswireTODAY - /newswire/ - Nottingham, United Kingdom, 2011/08/09 - PRECOS partners with reliable cancer therapies to provide rigorous scientific evidence for complementary cancer medicines - /

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has signed a partnership agreement with Reliable Cancer Therapies (RCT) to provide scientific validation of existing data for cancer therapies. The partnership will see PRECOS provide drug efficacy work to support RCT’s research on complementary medicines, so that evidence-based treatment choices can be made with confidence by patients and health professionals.

RCT is a Swiss private non-profit organisation dedicated to selectively funding the development of, and providing research-based information on, promising cancer therapies. Rigorous scientific research is required for any medical therapy for ethical and safety reasons and this also applies to therapies that use herbs, vitamins, minerals and other natural substances. Comprehensive research into complementary medicine is vital to ensure efficacy, safety, quality and cost-effectiveness of new therapies.

As a world leader in the provision of pre-clinical research and development services for oncology drug discovery, PRECOS evaluates oncology therapies for major pharmaceutical and biotech companies worldwide. As a result, the company is ideally placed to apply its proven scientific expertise to RCT’s projects. This partnership will see PRECOS validate RCT’s existing research using PRECOS’s unique expertise in validated patient relevant cancer models which includes in vitro 2D and 3D assays, in vivo therapeutic evaluations and post-study analyses on for example a total herbal extract to evaluate product efficacy and scientific validation.

“There is a need for reliable data of non-conventional cancer treatments,”
said Luc Verelst, founder of RCT. “The majority of the research conducted to date is not sufficiently scientifically or statistically rigorous to prove the benefits of these therapies. It is crucial for RCT to partner with a company with such a strong scientific reputation like PRECOS. With the support of such an innovative organisation in the oncology arena this situation can be improved and reliable, high quality scientific evidence can be provided.”

Dr. Neil Rotherham, chairman of the PRECOS board highlights: “Our advanced models challenge new therapeutic agents similar to the situation in the patient thereby providing more relevant and clinically predictive data which we have applied to a broad spectrum of therapies including complementary therapies. We are therefore well positioned to support RCT in such an exciting area of research.” Neil continues,“We are very excited to partner with RCT and to be able to provide robust scientific data for the evaluation of promising complementary cancer therapies. PRECOS is proud of our scientific expertise and are happy to be able to apply our innovative technologies to advance cancer treatment and care in any way possible, whether that is conventional or non-conventional cancer treatments.”

For more information on PRECOS, please call +44 (0)870 166 6234, email enquiries[.] or visit

For more information on RCT, email info[.] or visit the website.

About PRECOS Ltd
PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.

PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004, and in 2010 span out to become a standalone commercial entity, retaining close links to the University PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade.

About Reliable Cancer Therapies (RCT)
Reliable Cancer Therapies ( is a Swiss private non-profit organization selectively funding the development of promising therapies and providing research-based information on cancer therapies. The RCT website provides information on cancer types and treatments. The latter has been investigated for evidence and the investigation results are published on the website. This research based information is available in an adapted language for patients and their relatives, and for professionals so that it can be used to make an informed decision together with the oncologist on what treatment to follow. The RCT website facilitates patient access to information regarding clinical trials which could be a treatment option. RCT participates in recognized research through organizations such as the Verelst foundation for uterine cancer, based in Leuven, Belgium. RCT selectively provides funding for the clinical development of promising anti-cancer therapies/agents that fall outside the scope of the established clinical cancer research.

The RCT team is independent and open-minded, is supported by a high-level advisory board, is collaborating with international organizations (ESMO, CAM-CANCER) and consults reliable sources (National Cancer Institute, Memorial Sloan-Kettering Cancer Center, Natural Standard, a.o.). RCT does not provide individual medical advice and our website does not replace a medical consultation. To find out more about RCT, please visit the website.

Press contact RCT: Ann-Christine Moenaert – Reliable Cancer Therapies – Representative office Boechoutlaan 221, 1853 Strombeek-Bever, Belgium

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: The Scott Partnership


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick NewswireToday Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

PRECOS Partners with Reliable Cancer Therapies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Contact: Sarah Evans - 
+44(0)14 7753 9539 precos[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From The Scott Partnership / Company Profile

Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  Limelon Advertising, Co.

  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (